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Accumulated evidence has suggested that potentiation of cortical GABAergic inhibitory neurotransmission may be
a key mechanism in the treatment of schizophrenia. However, the downstream molecular mechanisms related to
GABA potentiation remain unexplored. Recent studies have suggested that dopamine D2 receptor antagonists,
which are used in the clinical treatment of schizophrenia, modulate protein kinase B (Akt)/glycogen synthase kinase
(GSK)-3 signaling. Here we report that activation of GABAB receptors significantly inhibits Akt/GSK-3 signaling in a
β-arrestin-dependent pathway. Agonist stimulation of GABAB receptors enhances the phosphorylation of Akt
(Thr-308) and enhances the phosphorylation of GSK-3α (Ser-21)/β (Ser-9) in both HEK-293T cells expressing GABAB
receptors and rat hippocampal slices. Furthermore, knocking down the expression of β-arrestin2 using siRNA
abolishes the GABAB receptor-mediated modulation of GSK-3 signaling. Our data may help to identify potentially
novel targets through which GABAB receptor agents may exert therapeutic effects in the treatment of
schizophrenia.Introduction
Schizophrenia (SCZ) is a debilitating disorder that exacts
enormous personal, social and economic costs. Accumu-
lated evidence has suggested that potentiation of cortical
GABAergic inhibitory neurotransmission may be a novel
treatment target for resistant SCZ. The human GABAB
receptor gene has been localized to regions in the gen-
ome associated with schizophrenia, 6p21.3 [1,2]. In
addition, the expression of the GABAB receptor has
been shown to be reduced in the human schizophrenic
brain [3]. As well, the GABAB receptor agonist, baclofen
has been reported to have some efficacy in SCZ patients
[4]. Baclofen was also shown to improve cognition in an
animal model of methamphetamine-induced psychosis
[5] and elicit antipsychotic-like effects in the rat para-
digm of prepulse inhibition of the startle response, an
animal phenotype for modeling SCZ [6].
Transcranial magnetic stimulation (TMS) indices of
GABAB receptor mediated inhibitory neurotransmission
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reproduction in any medium, provided the orcortical silent period (CSP) represents a TMS neuro-
physiological index of GABAB receptor mediated inhibi-
tory neurotransmission whereas short interval cortical
inhibition (SICI) represents a TMS neurophysiological
index of GABAA receptor mediated inhibitory neuro-
transmisssion. Both the CSP and SICI were lowered in
patients with SCZ [7,8]. Clozapine treated patients
demonstrated significantly longer CSP durations of large
effect (i.e., Cohen’s D > 3) but no change in SICI relative
to unmedicated SCZ patients and healthy subjects [9].
These findings suggest that clozapine potentiates the
GABAB receptor and also underscores the possibility
that the GABAB receptor may play a key role in the
treatment of SCZ. Furthermore, a recent in-vivo study
by Wu et al. also confirmed these findings [10] which
reported that the binding of the GABAB receptor antag-
onist [3H]-CGP54626A increased when treated with clo-
zapine. There was a significant correlation between the
clozapine dose and the increase of [3H]-CGP54626A bind-
ing in linear regression analysis. In the presence of cloza-
pine, a left shift was shown for specific [3H]-CGP54626A
binding in competition with different concentrations of
GABA. Clozapine also increased [3H]-CGP54626A bind-
ing at GABAB R1 subunit when HEK293 cells overex-
pressed GABAB receptors, highlighting a potential
therapeutic target for clozapine.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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named for its ability to phosphorylate and inactivate the
metabolic enzyme glycogen synthase [11]. Subsequently,
GSK-3 was found to be broadly involved in neural sys-
tems and modulate many aspects of neuronal function,
including gene expression, neurogenesis, synaptic plasti-
city, neuronal structure, and neuronal death and survival
[12-14]. Accumulating evidence implicates abnormal ac-
tivity of GSK-3 in psychiatric disorders, such as bipolar
disorder, depression, schizophrenia, ADHD and Alzhei-
mer’s Disease [15-17] and GSK-3 is a potential protein
kinase target for antipsychotics. Atypical antipsychotics,
such as clozapine and olanzapine, can regulate phospho-
serine-GSK-3 and inhibit its activity [18].
There are two highly homologous GSK-3 enzymes,
GSK-3α and GSK-3β, derived from separate genes. Both
GSK-3α and GSK-3β are expressed throughout the brain
[19] and they are regulated by several mechanisms. The
most well-defined regulatory mechanism is by phosphor-
ylation of serine-9 in GSK-3β or serine-21 in GSK-3α,
which inhibits GSK-3 activity [20-22]. The Akt signaling
pathway often is a major regulator of GSK-3 because Akt
phosphorylates GSK-3 on these inhibitory serine residues,
which has been shown to involved in dopamine signaling
and many aspects of psychiatric disorders [23]. Conversely,
enzymatic activity is enhanced by phosphorylation of
tyrosine-216 in GSK-3β and tyrosine-279 in GSK-3α,
which are autophosphorylation sites, and can facilitate
substrate binding to GSK-3, although the mechanism of
this modification are not well-defined [24].
The fact that all current antipsychotic drugs exert their
effect through the blockade of dopamine D2 receptors
(D2R) has established that increased D2R signaling is an
important part of the pathophysiology of schizophrenia
[25,26]. Recent studies have suggested that D2R can acti-
vate the Akt/GSK-3 pathway via G protein-independent
signaling [20,27]. D2R-mediated Akt/GSK-3 regulation
involves the recruitment of β-arrestin2 to the D2R and
specific dephosphorylation/inactivation of the serine/
threonine kinase Akt on its regulatory Thr-308 residue
but not the second regulatory residue (Ser-473) [20].
Phosphorylation of Akt in response to DA leads to a re-
duction of kinase activity and a concomitant activation
of its substrates GSK-3α (Ser-21)/β (Ser-9) [20]. More
importantly, antipsychotics including haloperidol, cloza-
pine and olanzapine strongly decrease recruitment of
β-arrestin2 to D2R [18,28,29]. These data support a crit-
ical role of D2R-mediated GSK-3 signaling in the path-
ology of schizophrenia and suggest that antipsychotics
exert their therapeutic effect by targeting GSK-3 signal-
ing. Therefore, we investigated whether activation of
GABAB receptors can modulate GSK-3 signaling. This will
be a step towards establishing the relationship between
the GABAB receptor and downstream targets ofantipsychotic action, and potentially identifying new
therapeutic targets for schizophrenia.
Materials and methods
Material
The cDNAs encoding human GABABR1a and GABABR2
subunits in pcDNA3 were kindly supplied by Dr. O. Carter
Snead in The Hospital for Sick Children in Toronto.
The β-arrestin2 siRNA targeting human β-arrestin2 were
purchased from Santa Cruz Biotechnology (cat# sc-29208).
Cell culture and transient transfection
HEK293T cells were cultured in α-MEM ( Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine
serum (Invitrogen) and maintained in incubators at
37°C, 5% CO2. HEK293T cells were grown to 90% con-
fluence before being transiently transfected with plasmid
constructs and/or siRNA using X-treme GENE 9 DNA
transfection reagents (Roche). About 24–48 hours after
transfection, cells were used for experiments.
Protein extracts isolation
Transfected HEK293T cells were collected, washed with
1 × PBS, and solubilized with the buffer (50 mM Tris–
HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, 2 mM EDTA, 1 mM PMSF, 1 mM Na3VO4,
4 mM NaF, 20 mM β-glycerophosphate and 5 μl/ml prote-
ase inhibitor cocktail (Sigma) and centrifuged at 10,000 g
at 4°C for 10 min. The concentration of supernatant was
qualified with a BCA protein assay. Finally, the samples
were boiled with SDS sample buffer for 5 min, and sub-
jected to SDS-PAGE for Western blot analysis.
Gel Electrophoresis and western blotting
Samples were separated by SDS-PAGE with 5% stacking
gel and 10% separating gel and transferred to a nitrocel-
lulose membrane. After blocking for 1 hour with 5% fat-
free milk powder in TBST (10 mM Tris–HCl, 150 mM
NaCl, 0.05% Tween-20, pH 7.4), blots were incubated
overnight at 4 °C with primary antibodies: 1:1,000 anti-
phosphorylated GSK-3α/β (Ser-21/ 9) (Cell Signaling
Technology), 1:1,000 anti-GSK-3α (Cell Signaling Tech-
nology), 1:1,000 anti-GSK-3β (Cell Signaling Technol-
ogy), 1:200 anti-β-arrestin2 (Santa Cruz Biotechnology),
1:10,000 anti-α-tubulin (Sigma), 1:1000 anti-GSK-3α/β
(Y-279/Y-216) (Millpore), 1:1000 anti-Akt (Abcam),
1:1000 anti-phosphorylated-Akt (Thr-308) (Cell Signal-
ing Technology), and 1:1000 anti-phosphorylated-Akt
(Ser-473) (Abcam). After washes, blots were incubated
with HRP-conjugated secondary antibodies (Sigma) for 2
hours at room temperature. Immunoactivity was visua-
lized with ECL Western blot detection reagents (GE
Healthcare). Data representative of three experimental
replicates are shown.
Lu et al. Molecular Brain 2012, 5:41 Page 3 of 10
http://www.molecularbrain.com/content/5/1/41Statistical analysis
All values are shown as means ± SEM. For comparisons
between two groups, t-tests were performed. For com-
parisons of more than two groups, one-way or two-way
ANOVA followed by the Student-Newman-Keuls post
hoc analysis was performed.
Results
Activation of GABAB receptors increases phosphorylated
GSK-3α/β at Ser-21/Ser-9 sites
Previous studies have suggested that phosphorylation of
GSK-3α/β at Ser-21/Ser-9 sites significantly decreasesp -GSK3 α (Ser21) 
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Figure 1 Activation of GABAB receptors elevates GSK-3α/β phosphory
of GSK-3α/β at Y279/Y216 sites in HEK293T cells expressing GABAB re
Ser-9) levels in extract prepared from HEK293T cells transfected with GABA
agonist. GSK-α/β was used as a loading control. B. Densitometric analysis o
GSK-3α/β was quantified by densitometry (software: Image J, NIH). C. West
extract prepared from HEK293T cells transfected with GABAB receptor in th
was used as a loading control. D. Densito-metric analysis of phosphorylate
quantified by densitometry (software: Image J, NIH). Data were analyzed byactive site availability, thus inhibiting GSK-3 activity
[30]. To investigate whether GABAB receptors are
involved in the GSK-3 signaling, we initially tested
whether activation of GABAB receptors can modulate
the phosphorylation of GSK-3α/β at Ser-21/Ser-9 sites
in HEK293T cells expressing GABABR1a and GABABR2
subunits. As shown in Figure 1A, SKF97541 (1 μM,
30 min), a specific GABAB receptor agonist significant-
ly increased GSK-3α/β (Ser-21/Ser-9) phosphorylation,
an effect that can be blocked by the GABAB receptor-
specific antagonist CGP52432 (10 μM, 30 min).
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one-way ANOVA (*P < 0.05, **P < 0.01, n = 3).
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phorylation, suggesting that GABAB receptors may
have constitutive activity that is consistent with previ-
ous reports [31]. The total expression of GSK 3α/β is
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Figure 2 Activation of GABAB receptors elevates Akt (Thr-308) phosp
can be blocked with pretreatment of PI3K inhibitor Wortmannin. A. W
levels in extract prepared from HEK 293T cells transfected with GABAB rece
was used as a loading control. B-C. Densitometric analysis of phosphorylat
was quantified by densitometry (software: Image J, NIH). D. Western blot a
in extract prepared from HEK293T cells transfected with GABAB receptor pr
absence of GABAB receptor agonist SKF97541. E. Densitometric analysis of
GSK-3α/β (Ser-21/Ser-9) was quantified by densitometry (software: Image J,
**P < 0.01, n = 3).each protein expression was quantified using dentito-
metry (Figure 1B). These data suggest that activation
of GABAB receptors may enhance GSK-3α/β (Ser-21/
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phosphorylated GSK-3α/β at Y-279/Y-216 sites
Previous studies have suggested that phosphorylation at
the tyrosine-216 site of GSK-3β or tyrosine-279 of GSK-
3α enhances the enzymatic activity of GSK-3. We have
shown that activation of GABAB receptors may inhibit
GSK-3 activity by enhancing GSK-3α/β (Ser-21/Ser-9)
phosphorylation. We then tested whether activation of
GABAB receptors can inhibit GSK-3 activity by inhibiting
GSK-3α/β phosphorylation at the Y-279/Y-216 sites of
GSK-3α/β. As shown in Figure 1C-D, activation of GABAB
receptors has no effect on GSK-3α/β (Y-279/Y-216) phos-
phorylation. These data suggest that GABAB receptors
may modulate GSK-3 activity by selectively phosphorylat-
ing GSK-3α/β at the Ser-21/Ser-9 sites.
Activation of GABAB receptors significantly enhances Akt
phosphorylation at Thr-308
Previous studies have shown that GSK-3α/β activity can
be negatively regulated by Akt, a serine/threonine kin-
ase. Dephosphorylation of Akt on its regulatory Thr-308
site leads to a reduction of Akt kinase activity that
induces the activation of its substrate GSK-3 [32]. Since
we have observed enhanced GSK-3α/β (Ser-21/Ser-9)
phosphorylation upon activation of GABAB receptors,
we hypothesized that Akt phosphorylation may also be
modulated by the activation of GABAB receptors. As
shown in Figure 2A-C, GABAB receptor stimulation sig-
nificantly enhances Akt phosphorylation at Thr-308, but
not at Ser-473. These data are consistent with previous
studies on dopamine D2 receptor activation of GSK-3
signaling although the direction of effect is opposite.
To further confirm the requirement of Akt activation
in the GABAB receptor-mediated GSK-3 signaling, we
tested whether phosphatidylinositol 3-kinases (PI3K) in-
hibitor can block the GABAB receptor-mediated GSK-3
phosphorylation as previous studies have shown block-
ade of PI3K inhibits Akt activity [33]. As shown in
Figure 2D-E, wortmannin (100 nM, 24 h), a PI3K inhibi-
tor, block the effect of GABAB receptor on the phos-
phorylation of GSK3 at Ser21/Ser9 sites, further
confirming the requirement of Akt in the GABAB
receptor-mediated GSK-3 signaling.
GABAB receptors modulate GSK-3α/β phosphorylation
through a Gi-protein-independent/
β-arrestin2-dependent pathway
Both GABAB and dopamine D2 receptors are Gi/o-
coupled receptors. Traditionally, G-protein coupled
receptors exert their effects only via G-protein mediated
signaling. However, recent studies have suggested that
dopamine D2 receptors can activate the Akt/GSK-3 path-
way via G-protein independent/β-arrestin2-dependent sig-
naling [20,27]. Thus, we tested whether Gi/o protein andβ-arrestin2 are involved in the GABAB receptor-mediated
modulation of GSK-3 signaling. As shown in Figure 3A-B,
pre-incubating the cells expressing GABAB receptor or
primary cultured hippocampal neurons (Figure 4C-D)
with pertussis toxin (PTX) (200 ng/ml, 14–18 h), which
uncouples the receptors from Gi/o protein, has no effect
on GABAB receptor-mediated modulation of the phos-
phorylation of GSK-3α/β (Ser-21/Ser-9). This result sug-
gests that GABAB receptors modulate phosphorylation of
GSK-3α/β through a Gi-protein-independent pathway.
We then confirmed the efficiency of β-arrestin2 siRNA
for knocking-down the expression of β-arrestin2. As
shown in Figure 3C, the expression of β-arrestin2 in
HEK-293T cells is significantly decreased when trans-
fected with β-arrestin2 siRNA (Santa Cruz Biotechnol-
ogy), compared to cells transfected with control siRNA.
We then measured the phosphorylation of GSK-3α/β
(Ser-21/Ser-9) in HEK-293T cells transfected with
GABAB receptors and β-arrestin2 siRNA or control
siRNA. As shown in Figure 3D-E, activation of GABAB
receptors significantly enhanced the phosphorylation of
GSK-3α/β (Ser-21/Ser-9) in HEK-293T cells transfected
with GABAB receptors and control siRNA, while activa-
tion of GABAB receptors failed to alter the phosphoryl-
ation of GSK-3α/β (Ser-21/Ser-9) in HEK-293T cells
transfected with GABAB receptors and β-arrestin2
siRNA. These data indicate that β-arrestin2 is required
for GABAB receptor-mediated modulation of GSK-3
signaling.
Activation of GABAB receptors increases phosphorylated
GSK-3α/β at Ser-21/Ser-9 sites in rat hippocampal slices
To examine the effect of GABAB receptor on GSK-3 sig-
naling in a relevant cellular milieu, rat hippocampal
slices were utilized in parallel experiments. As shown in
Figure 4A-B, pre-treatment of the hippocampal slices
with the GABAB receptor specific agonist SKF97541 sig-
nificantly enhanced the phosphorylation of GSK-3α/β
(Ser-21/Ser-9). Consistent with the data obtained in
HEK-293T cells transfected with GABAB receptors,
GABAB receptor antagonist CGP52432 abolished the
GABAB receptor effect on phosphorylation of GSK-3α/β
(Ser-21/Ser-9). These data further confirm that GABAB
receptors are involved in GSK-3 signaling.
Discussion
Our findings suggest that activation of GABAB inhibits
GSK-3 signaling through a β-arrestin2-dependent pathway
(Figure 5). This pathway involves the upregulation of Akt
phosphorylation at Thr-308 and GSK-3α/β phosphoryl-
ation at Ser-21/Ser-9. As a G-protein coupled receptor
(GPCR), the GABAB receptor was thought to exert its
effects via coupling to pertussis toxin (PTX) sensitive Gi/o
proteins, that in turn regulate voltage-gated Ca2+ (CaV) or
p-GSK3 α (Ser21)
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Figure 3 Effect of GABAB receptors on GSK-3α/β phosphorylation is a Gi protein-independent/β-arrestin2-dependent pathway in
HEK293T cells expressing GABAB receptors. A. Western blot analysis of phosphorylated GSK-3α/β (Ser-21/Ser-9) levels in extract prepared from
HEK293T cells transfected with GABAB receptors in the presence or absence of GABAB receptor agonist with/without PTX (200 ng/ml, 14–18 h).
GSK-3α/β was used as a loading control. B. Densitometric analysis of phosphorylated GSK-3α/β (Ser-21/Ser-9). C. Western blot analysis of efficacy
of β-arrestin2 siRNA on β-arrestin2 express in HEK293T cells. D. Western blot analysis of phosphorylated GSK-3α/β (Ser-21/Ser-9) levels in extract
prepared from HEK293T cells transfected with GABAB receptors and β-arrestin2 siRNA or control siRNA in the presence or absence of GABAB
receptor agonist. GSK-3α/β was used as a loading control. E. Densitometric analysis of phosphorylated GSK-3α/β (Ser-21/Ser-9). The intensity of
phospho-GSK-3α/β was quantified by densitometry (software: Image J, NIH). Data were analyzed by two-way ANOVA(*P < 0.05, **P < 0.01, n = 3).
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and inhibit adenylyl cyclase. However, our results suggest
that activation of GABAB receptor modulates GSK-3 sig-
naling in a G-protein independent manner, as PTX failed
to block the GABAB receptor effect on GSK-3α/βphosphorylation. Interestingly, previous studies have
shown that activation of dopamine D2 receptors, which
are also Gi/o coupled GPCRs, similarly modulate GSK-3
signaling in a β-arrestin dependent pathway. However,
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Figure 4 Activation of GABAB receptors elevates GSK-3α/β phosphorylation in rat hippocampal slices, and this effect can not be
blocked by PTX when pretreating primary cultured hippocampal neurons. A. Western blot analysis of phosphorylated GSK-3α/β
(Ser-21/Ser-9) levels in extract prepared from rat hippocampal slices in the presence of GABAB receptor agonist and/or antagonist. GSK-3α/β was
used as a loading control. B. Densitometric analysis of phosphorylated GSK-3α/β (Ser-21/Ser-9). C. Western blot analysis of phosphorylated
GSK-3α/β (Ser-21/Ser-9) levels in extract prepared from rat primary cultured hippocampal neurons pretreated with PTX (200 ng/ml, 14–18 h) in
the presence or absence of GABAB receptor agonist SKF97541. GSK-3α/β was used as a loading control. D. Densitometric analysis of
phosphorylated GSK-3α/β (Ser-21/Ser-9). The intensity of phospho-GSK-3α/β was quantified by densitometry (software: Image J, NIH). Data
were analyzed by one-way or two-way ANOVA (*P < 0.05, **P < 0.01,***P < 0.001, n = 3).
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β-arrestin2 recruitment to the D2 receptors and formation
of a β-arrestin2-scaffolded protein complex that includes
protein phosphatase 2A (PP2A), Akt and GSK-3α/β. PP2A
dephosphorylates Akt at Thr-308 which subsequent acti-
vation of GSK-3α/β as a consequence of dephosphoryla-
tion of GSK-3 at Ser-9 and 21 [34]. It is worth noting that
both receptors modulate GSK-3 signaling by changing the
Akt phosphorylation at Thr-308 site and GSK 3α/β phos-
phorylation at Ser-21/Ser-9 sites. The fact that both
GABAB receptor agonists and D2 receptor antagonists
exert antipsychotic effects [5,35], together with previous
findings that antipsychotics are potent antagonists of thedopamine-induced recruitment of β-arrestin2 to the D2
receptors [36], suggests that inhibition of GSK-3 activity
may be a molecular mechanism through which GABAB
receptor agonists have antipsychotic effects.
Previous studies have suggested that GPCRs can signal
without an external chemical trigger, i.e., in a constitu-
tive or spontaneous manner [36]. For example, dopa-
mine D5 receptors enhance cAMP accumulation
without agonist stimulation [38,39]. Consistent with this
idea, GABAB receptors also display constitutive activity
as we observed a significant decrease of GSK-3α/β phos-
phorylation at Ser-21/Ser-9 sites treated only with the
GABAB receptor antagonist CGP52432. The general
Schematic Model of GABABR-mediated GSK-3 pathway 
P 
P 










































Figure 5 Schematic model of GABAB receptor mediated GSK-3 signaling. Activation of GABAB receptors enhances the phosphorylation of
Akt and GSK-3α/β, which inactivates GSK-3 signaling. Activation of D2 receptors has the opposite effect as previously reported [37].
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permit bi-direction control of receptor activity. With
constitutively active pathways, the output can be either
increased or decreased from a mid-range level.
GSK-3 is a multi-functional serine/threonine kinase.
Its activity is regulated negatively by the phosphorylation
of Ser-9 and positively by the phosphorylation of Tyr-
216, a GSK-3β auto-phosphorylation site required for
regulating its activity. Previous studies have shown that
GSK-3β phosphorylsation at Tyr-216 can be prevented
by its interaction with DISC1 (Disrupted-in-schizophre-
nia-1 protein) [40]. Thus, it is possible that GABAB
receptors inhibit GSK-3 activity through direct inhibition
of GSK-3β phosphorylsation at Tyr-216 site. However,
our results indicate that activation of GABAB receptors
has no effect on GSK-3β phosphorylation at Tyr-216.
Interestingly, this data is also consistent with the dopa-
mine D2 receptor effect on GSK-3 phsphorylation as ac-
tivation of D2 receptor also has no effect on GSK-3β
phosphorylation at Tyr-216.
Available evidence suggests that antipsychotic drugs
exert their antipsychotic effects in schizophrenia through
the blockade of dopamine D2 receptors (D2R) or D2R in
combination with the serotonin receptor 2A (5-HT2AR)
[25,26,41]. GABAB receptors and D2R belong to the
super family of G-protein coupled receptors (GPCRs)
that exert their biological effects via intracellular G
protein-coupled signaling cascades [42-45]. D2Rs display
a complex pattern of signal transduction via their coup-
ling to the Gi/Go protein. Previously, D2Rs were known
to stimulate a number of signal transduction pathways
including the inhibition of adenylate cyclase activity, PI(phosphatidylinositol) turnover, potentiation of arachi-
donic acid release, inwardly rectifying K+ and Ca2+ chan-
nels and mitogen activated protein kinases [43]. Recently
several studies have suggested that D2R can activate the
Akt/GSK-3 pathway via β-arrestin2-dependent signaling.
D2R-mediated Akt/GSK-3 regulation involves the re-
cruitment of β-arrestin2 to the D2R and the formation
of signaling complexes containing β-arrestin2, protein
phosphatase 2A (PP2A) and Akt. Formation of this
protein complex leads to specific dephosphorylation/
inactivation of the serine/threonine kinase Akt on its
regulatory Thr-308 residue but not the second regula-
tory Ser-473 residue [23,27,43] the inactivation of Akt,
in response to DA stimulation, leads to a reduction of
kinase activity and a concomitant activation of its sub-
strates GSK-3α (Ser-21)/β (Ser-9) since both are nega-
tively regulated by Akt [20]. Interestingly, D2R-mediated
modulation of GSK-3 signaling targets the same phos-
phorylation sites as GABAB receptors, but the functional
effects are the opposite. The fact that antipsychotics
block D2R and also antagonize the agonist-induced re-
cruitment of β-arrestin2 to D2R [29], supports our con-
tention that GABAB receptor-mediated inhibition of
GSK-3 signaling may be a target for the development of
novel antipsychotic medications.
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